Navigation Links
Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
Date:10/31/2011

TAMPA, Fla. (Oct. 31, 2011) Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

"Tregs play a dominant role in transplantation tolerance," said Claudio Anasetti, M.D., corresponding author of a study carried out by a team of Moffitt investigators and published in a recent issue of the journal Blood. "Adoptive transfer of freshly isolated human Tregs has prevented GVHD in patients treated with allogeneic (other than self-donated) stem cell transplants. However, some transplants will require a greater number of Tregs that can only be obtained through expanding Tregs outside of the body."

The researchers suggest that therapeutic applications will require Tregs to be expanded by more than a hundredfold.

"There is a need to improve on Treg expansion protocols before allo-specific Tregs can be brought into the clinic," said Anasetti, chair of the Department of Blood & Marrow Transplant at Moffitt.

The authors note that a recently adopted expansion process has used dendritic cells to activate Tregs.

"Dendritic cells have been identified as having unique capabilities for expanding Tregs," cited Anasetti, whose work focuses on preventing GVHD in mouse models and in humans.

To carry out the present study, Anasetti and his fellow researchers adopted a one-step process to expand allo-specific Tregs by dendritic cell stimulation.

"Our work opens an opportunity to study tissues as sources of antigens for indirect presentation to activate and expand therapeutic Tregs," concluded Anasetti. "If effective, this approach could prevent GVHD while sparing, at least in part, graft-versus-leukemia or graft-versus-tumor responses."


'/>"/>

Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers find more clues to causes of breast cancer
2. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
3. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
4. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
5. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
6. Computer-based tool to improve diagnosis and prognosis for cancer patients
7. Research highlights training to improve colorectal cancer detection
8. Mayo Clinic: Short training course significantly improves detection of precancerous polyps
9. First-of-its-kind study creates new tool for targeted cancer drug development
10. Controlling gene expression to halt cancer growth
11. Fighting a smarter war against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , ... September 25, 2017 , ... Earlypicker is expanding ... a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the nation. ... company that’s already well-known for the great offerings that allow Koreans everywhere to look ...
(Date:9/25/2017)... ... ... Majestic Unicorn”: a poignant book that describes what happened to the animals—specifically on ... Dayna Chantel, an artist and a writer. , Chantel shares, “Animals of all kinds, ... Male and female, no matter what species, they were chosen to be saved. The ...
(Date:9/25/2017)... ... ... Borers kill Ash trees in as little as 1-3 years. The signs of ... Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in Northeast ... of decline from Emerald Ash Borers, two Ash trees continue to thrive. , ...
(Date:9/24/2017)... ... September 23, 2017 , ... Throughout the United States and the world, clinicians ... physicians, nurses and other providers work to give the best care possible to patients ... But U.S. Senators today are threatening to tie our hands in carrying out that ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “Star of ... “Star of Bethlehem Study” is the creation of published author, Duane Engdahl, an investigator ... Published by Christian Faith Publishing, Duane Engdahl’s new book is a thought-provoking essay an ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
Breaking Medicine Technology: